The thermal decomposition mechanism of Irbesartan (cas 138402-11-6)
-
Add time:08/27/2019 Source:sciencedirect.com
Irbesartan (IBS) is an inhibitor of angiotensin II receptor. In order to study the thermal stability and the thermal decomposition mechanism of IBS, the thermal decomposition processes of IBS in nitrogen and in air atmospheres were studied by means of thermogravimetry (TG) and differential scanning calorimetry (DSC), the evolved gaseous products from thermal decomposition were identified with thermogravimetry coupled with Fourier transform infrared spectroscopy (TG-FTIR), and the residues of thermal decomposition at various temperatures were analyzed with infrared spectra, high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC–MS). The molecular bond orders were calculated by GAMESS program of quantum chemistry, and the thermal decomposition mechanism of IBS was discussed. The results indicated that the thermal decomposition of IBS is a three-stage process and the initial temperatures of the decomposition are 204.7 and 201.0 °C in nitrogen and in air, respectively. The initial step of the decomposition is the partial decomposition of imidazolone and tetrazol sections. The thermal stability of IBS is quite good in the routine temperature.
We also recommend Trading Suppliers and Manufacturers of Irbesartan (cas 138402-11-6). Pls Click Website Link as below: cas 138402-11-6 suppliers
Prev:Immunopharmacology and inflammationSuppressive effects of type I angiotensin receptor antagonists, candesartan and Irbesartan (cas 138402-11-6) on allergic asthma
Next:Original ArticleTargeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by Irbesartan (cas 138402-11-6) to ameliorate doxorubicin-induced hepatotoxicity☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with Irbesartan (cas 138402-11-6) in a rat model of diabetic nephropathy09/01/2019
- Original ArticleChronomodulated drug delivery system of Irbesartan (cas 138402-11-6): Formulation and development using Desing of Experiment (DoE)08/31/2019
- Irbesartan (cas 138402-11-6) attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway08/30/2019
- Exploring the interactions of Irbesartan (cas 138402-11-6) and Irbesartan (cas 138402-11-6)–2-hydroxypropyl-β-cyclodextrin complex with model membranes08/29/2019
- Original ArticleTargeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by Irbesartan (cas 138402-11-6) to ameliorate doxorubicin-induced hepatotoxicity☆08/28/2019
- Immunopharmacology and inflammationSuppressive effects of type I angiotensin receptor antagonists, candesartan and Irbesartan (cas 138402-11-6) on allergic asthma08/26/2019
- Irbesartan (cas 138402-11-6) desmotropes: Solid-state characterization, thermodynamic study and dissolution properties08/25/2019
- Downstream processing of Irbesartan (cas 138402-11-6) nanocrystalline suspension and mini-tablet development – Part II08/24/2019
- ReviewShould we add atorvastatin to Irbesartan (cas 138402-11-6) for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials08/23/2019
-
Health and Chemical more >
-
Related Products


